NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis $9.56 +0.25 (+2.69%) As of 10/14/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Atara Biotherapeutics Stock (NASDAQ:ATRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atara Biotherapeutics alerts:Sign Up Key Stats Today's Range$9.20▼$9.9950-Day Range$8.05▼$10.2352-Week Range$3.92▼$19.15Volume39,595 shsAverage Volume41,242 shsMarket Capitalization$95.98 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Atara Biotherapeutics, Inc. is a biotechnology company focused on developing T-cell immunotherapies for cancer and serious diseases associated with viral infections. The company’s approach uses allogeneic, or donor-derived, T cells that are selected or engineered to recognize disease-related targets, with the goal of providing off-the-shelf treatment options. Atara’s lead product, Ebvallo (tabelecleucel), is an allogeneic T-cell immunotherapy designed to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in certain patients who have received a solid-organ or hematopoietic-cell transplant. Ebvallo received marketing authorization in the European Union and is commercialized in international markets through collaboration arrangements. The company has also developed investigational programs in areas including multiple sclerosis and oncology, although its pipeline has changed over time as programs have advanced or been discontinued. Founded in 2012 and headquartered in Thousand Oaks, California, Atara has focused primarily on serving patients in the United States and international markets through regulatory submissions, partnerships and commercialization agreements. Pascal Touchon has served as the company’s president and chief executive officer. As with other biotechnology companies, Atara’s product portfolio and corporate structure may change as clinical, regulatory and commercial activities progress.AI Generated. May Contain Errors. Read More Atara Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreATRA MarketRank™: 1.91128076872 of 5 starsAtara Biotherapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 679th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingModerate Buy Consensus RatingAtara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Atara Biotherapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($0.22) to $1.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -8.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -8.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Atara Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.45% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 8.11.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 20.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.07 News SentimentAtara Biotherapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Atara Biotherapeutics this week, compared to 5 articles on an average week. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $959,093.00 in company stock, which represents 0.9992% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have bought 2,344.91% more of their company's stock than they have sold. Specifically, they have bought $999,994.00 in company stock and sold $40,901.00 in company stock.Percentage Held by Insiders41.20% of the stock of Atara Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRA Stock News HeadlinesAtara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug AdministrationOctober 14 at 5:50 PM | marketscreener.comMAtara Biotherapeutics (NASDAQ:ATRA) Share Price Crosses Below 50-Day Moving Average - What's Next?October 9, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Atara Resubmits Tabelecleucel BLA To FDASeptember 30, 2026 | rttnews.comAtara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug AdministrationSeptember 30, 2026 | businesswire.comAtara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational ProgressAugust 12, 2026 | finance.yahoo.comAtara Biotherapeutics Announces $15 Million Registered Direct OfferingJuly 7, 2026 | businesswire.comQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic LeukemiaJune 11, 2026 | globenewswire.comSee More Headlines ATRA Stock Analysis - Frequently Asked Questions How have ATRA shares performed this year? Atara Biotherapeutics' stock was trading at $18.09 at the beginning of the year. Since then, ATRA shares have decreased by 47.2% and is now trading at $9.56. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings data on Wednesday, August, 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.01. The biotechnology company had revenue of $0.63 million for the quarter, compared to the consensus estimate of $0.55 million. When did Atara Biotherapeutics' stock split? Shares of Atara Biotherapeutics reverse split on the morning of Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Atara Biotherapeutics IPO? Atara Biotherapeutics (ATRA) raised $75 million in an initial public offering (IPO) on Thursday, October 16th 2014. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Allogene Therapeutics (ALLO), CRISPR Therapeutics (CRSP), Micron Technology (MU), AT&T (T), NVIDIA (NVDA), Tesla (TSLA) and Alibaba Group (BABA). Company Calendar Last Earnings8/12/2026Today10/14/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, ATRA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATRA CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees10Year Founded2012Price Target and Rating Average Price Target for Atara Biotherapeutics$9.50 High Price Target$13.00 Low Price Target$6.00 Potential Upside/Downside-0.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$32.69 million Net Margins-269.42% Pretax Margin-268.95% Return on EquityN/A Return on Assets-73.01% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.98 Sales & Book Value Annual Sales$120.77 million Price / Sales0.79 Cash Flow$5.01 per share Price / Cash Flow1.91 Book Value($5.34) per share Price / Book-1.79Miscellaneous Outstanding Shares10,040,000Free Float5,902,000Market Cap$95.98 million OptionableNo Data Beta0.21 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ATRA) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
